Abstracts Archive - Page 1311 of 2425 - ACR Meeting Abstracts

Abstract Number: 1582 • 2017 ACR/ARHP Annual Meeting
RORγt Inhibition Selectively Targets Pathogenic Subsets of Human iNKT and γδ-T Cells Enriched in Spondyloarthritis While Preserving Tissue Protective IL-22 Responses
Koen Venken^1,2, Mark Labadia³, Kathleen Hoyt³, Anita Wayne³, Robert Hughes³, Michael Turner³, Dustin Smith⁴, Christian Harcken⁴, Tine Decruy^5,6, Joseph Wahle⁷, Chao-Ting Wang³, Peggy Jacques⁸, Sofie Van Gassen⁹, Gaëlle Varkas¹⁰, Heleen Cypers¹⁰, Filip van Den Bosch¹¹, Yvan Saeys⁹, Gerald Nabozny¹² and Dirk Elewaut^13,14, ¹Department of Rheumatology, Faculty of Medicine and Health Sciences, Laboratory for Molecular Immunology and Inflammation,, Ghent, Belgium, ²VIB Inflammation Research Center, Ghent University, Ghent, Belgium, ³Research and Development Boehringer-Ingelheim, Ridgefield, CT, ⁴Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁵Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium, Ghent, Belgium, ⁶VIB Inflammation Research Center, Ghent, Belgium, ⁷Department of Immunology and respiratory discovery research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium, ¹⁰Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ¹¹Rheumatology, Ghent University Hospital, Gent, Belgium, ¹²[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ¹³VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, ¹⁴Department of Rheumatology, Laboratory for molecular immunology and inflammation, Ghent, Belgium
Background/Purpose: Dysregulated IL-23/IL-17 responses have been linked to a myriad of inflammatory diseases including psoriasis, psoriatic arthritis and other forms of spondyloarthritides (SpA). IL-23/IL-17 inflammation…
Abstract Number: 1583 • 2017 ACR/ARHP Annual Meeting
Increase in Arginase Activity and Related Arginine Metabolites in Patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA): Potential Mechanisms for Endothelial Dysfunction
M. Elaine Husni¹, Vandana Rai², Marcia Leon Rabanal³ and Unnikrishnan Chandrasekharan⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
Background/Purpose: A high prevalence of CVD exists among patients with PsA and RA. The cardiovascular morbidity and mortality are hypothesized to be due in part…
Abstract Number: 1584 • 2017 ACR/ARHP Annual Meeting
Chlamydia-Infected Macrophages: “Trojan Horses” for Dissemination of IL-23 and TNF-Mediated Inflammation in SKG Mouse Reactive Arthritis
Athan Baillet¹, Zaied Ahmed Bhuyan², Claire Douillard¹, Aurélie Bozon¹, Charles Armitage³, Xavier Romand¹, Minh Vu Chuong Nguyen¹, Bertrand Favier¹, Timothy Wells², Kenneth Beagley³ and Ranjeny Thomas², ¹Université Grenoble-Alpes, GREPI EA7408, Grenoble, France, ²The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ³Institute of Health & Biomedical Innovation, Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia
Background/Purpose: The sterile inflammatory arthritis associated with spondylitis, uveitis and rash, known as reactive arthritis, commences a few weeks after certain gastrointestinal or genitourinary infections,…
Abstract Number: 1585 • 2017 ACR/ARHP Annual Meeting
Role of Corticosteroids in Subclinical Atherosclerosis in SLE: A Systematic Review and Meta-Analysis
Ehsan Rajabirostami¹, Kam Newman², Sreelakshmi Panginikkod¹, Shahrzad Mohammadiankhansari¹, Nader Mehri³, Roshanak Habibi⁴ and Manish Jain⁵, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Rheumatology, Eisenhower Medical Center, Rancho Mirage, CA, ³Social Gerontology, Miami University, Oxford, OH, ⁴Presence Saint Francis Hospital, Evanston, IL, ⁵Rheumatology, Presence Saint Francis Hospital, Evanston, IL
Background/Purpose: Atherosclerosis in SLE results from a complex interplay between traditional risk factors, SLE-specific factors, chronic inflammation and multifaceted effects of SLE therapeutics. In particular,…
Abstract Number: 1586 • 2017 ACR/ARHP Annual Meeting
Resistant Hypertension Is Associated with Inflammation, Renal Function, and Increased Mortality in Patients with Systemic Lupus Erythematosus
Jocelyn Gandelman¹, Megan Shuey², April Barnado³, Li Wang⁴, C. Michael Stein³ and Cecilia P. Chung³, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Department of Pharmacology, Vanderbilt University, Nashville, TN, ³Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Resistant hypertension (RHTN) is defined as blood pressure that remains >140/90 mm Hg despite concurrent use of three different antihypertensive drugs. RHTN has an…
Abstract Number: 1587 • 2017 ACR/ARHP Annual Meeting
Mycobacterial Infection in Systemic Lupus Erythematosus: Clinical Significance and Associated Factors. Data from the Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)
Ana Lois-Iglesias¹, Víctor del Campo-Pérez², Iñigo Rúa-Figueroa³, Coral Mouriño-Rodriguez⁴, Francisco Javier López Longo⁵, María Galindo⁶, Jaime Calvo-Alen⁷, Jesús Ibañez Ruán⁸, Alejandro Olivé⁹, Rafael-Benito Melero González⁴, Antonio Fernandez-Nebro¹⁰, José Antonio Bernal¹¹, Celia Erausquin¹², Eva Tomero¹³, Maria Loreto Horcada¹⁴, Esther Uriarte¹⁵, Mercedes Freire¹⁶, Carlos Alberto Montilla-Morales¹⁷, Ana Sánchez Atrio¹⁸, Alina Boteanu¹⁹, Elvira Diez Alvarez²⁰, Javier Narváez²¹, Víctor Martínez Taboada²², Lucía Silva Fernández²³, Esther Ruiz Lucea²⁴, Jose Luis Andreu²⁵, José Hernández Beiraín²⁶, Marian Gantes²⁷, Blanca Hernández-Cruz²⁸, Jose Javier Perez Venegas²⁹, Ángela Pecondón Español³⁰, Nuria Lozano-Rivas³¹, Monica Ibanez Barcelo³², Gema Bonilla³³, Vicente Torrente³⁴, Ivan Castellví³⁵, Juan José Alegre³⁶, Mireia Moreno³⁷, José Luis Marenco de la Fuente³⁸, Cesar Magro-Checa³⁹, Tomás Vázquez Rodríguez⁴⁰, Victor Quevedo⁴¹, Patricia Richi⁴², Maria Teresa Oton Sanchez⁴³ and JM Pego-Reigosa⁴⁴, ¹Rheumatology, University Hospital A Coruña, A Coruña, Spain, ²Preventive Medicine and Epidemiology, EOXI Vigo, Vigo, Spain, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Rheumatology, EOXI Vigo, Vigo, Spain, ⁵Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ⁸POVISA, Rheumatology, Vigo, Spain, ⁹Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁰Rheumatology, Regional Universitary Hospital of Málaga, Malaga, Spain, ¹¹Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ¹²Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ¹³Hospital La Princesa. Madrid., Madrid, Spain, ¹⁴Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁵Reumatología, Hospital de Donosti, Donosti, Spain, ¹⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁷Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁸University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ¹⁹University Hospital Ramón y Cajal, Madrid, Spain, ²⁰Complejo Asistencial Universitario de León. León. Spain, León, Spain, ²¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ²³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²⁴Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ²⁸Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ²⁹Rheumatology, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ³⁰Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ³¹Rheumatology, Hospital Virgen de la Arrixaca, murcia, Spain, ³²H. Son Llatzer, Palma de Mallorca, Spain, ³³Hospital Universitario La Paz, Madrid, Spain, ³⁴Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁵Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ³⁶Sección de Reumatología Hospital Universitario Dr Peset Valencia, Valencia, Spain, ³⁷Rheumatology, Hospital Universitari Parc Taulí, Sabadell, Spain, ³⁸Rheumatology, Hospital de Valme, Seville, Spain, ³⁹Department of Rheumatology, Leiden University Medical Center, Leiden, Spain, ⁴⁰Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Hospital Infanta Sofía, Madrid, Spain, ⁴³Rheumatology Department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ⁴⁴Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: The aim of this work is to study the prevalence of mycobacterial infection (M.I.), the associated factors and their clinical significance in patients included…
Abstract Number: 1588 • 2017 ACR/ARHP Annual Meeting
“Neoplasia in Patients with Systemic LUPUS Erythematosus in Spain: Relesser Registry DATA”
Ana Urruticoechea-Arana¹, Iñigo Rúa-Figueroa², Maria Auxiliadora Martin³, Fernando Sánchez-Alonso⁴, Francisco Javier López Longo⁵, María Galindo⁶, Alejandro Olivé⁷, Jaime Calvo-Alen⁸, Antonio Fernandez-Nebro⁹ and JM Pego-Reigosa¹⁰, ¹Rheumatology, Hospital de Can Mises, Ibiza, Spain, ²Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ³Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ⁴Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ⁹Rheumatology, Regional Universitary Hospital of Málaga, Malaga, Spain, ¹⁰Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: There is limited evidence on the risk of neoplasia in autoimmune diseases such as systemic lupus erythematosus. The objective of this study is to…
Abstract Number: 1589 • 2017 ACR/ARHP Annual Meeting
A Multicriteria Decision Analysis for the Development of New Systemic Lupus Erythematosus Classification Criteria
Sara K. Tedeschi¹, Sindhu Johnson², Dimitrios Boumpas³, David I. Daikh⁴, Betty Diamond⁵, Thomas Doerner⁶, Søren Jacobsen⁷, Diane L. Kamen⁸, W. Joseph McCune⁹, Marta Mosca¹⁰, Rosalind Ramsey-Goldman¹¹, Guillermo Ruiz-Irastorza¹², Matthias Schneider¹³, Josef S. Smolen¹⁴, Murray Urowitz¹⁵, David Wofsy¹⁶, Martin Aringer¹⁷, Raymond P. Naden¹⁸ and Karen H. Costenbader^19,20, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ³University of Athens, Athens, Greece, ⁴Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁵Feinstein Institute for Medical Research, Manhasset, NY, ⁶Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany, ⁷Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁸Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁹Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ¹⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ¹¹FSM, Northwestern University, Chicago, IL, ¹²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain, ¹³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹⁴Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Rheumatology, UCSF, San Francisco, CA, ¹⁷Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ¹⁸New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ¹⁹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²⁰Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: EULAR and ACR are supporting multi-phase development of SLE classification criteria based on weighted criteria and a continuous probability scale. Prior steps included criteria…
Abstract Number: 1590 • 2017 ACR/ARHP Annual Meeting
Prolonged Antimalarial Treatment Increases the Risk for Severe Brady-Arrhythmias in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Paula Harvey³, Jiandong Su⁴ and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Severe brady-arrhythmias [complete atrioventricular block (cAVB) and sick sinus syndrome (SSS)] have a prevalence of 0.04% and 0.8% in the general population respectively and…
Abstract Number: 1591 • 2017 ACR/ARHP Annual Meeting
Monophasic Disease Course Pattern in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Zahi Touma³, Jiandong Su⁴, Nicole Anderson² and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Disease course in systemic lupus erythematosus (SLE) is believed to follow three distinct patterns over time, namely relapsing-remitting, persistently active and prolonged quiescent. We…
Abstract Number: 1592 • 2017 ACR/ARHP Annual Meeting
Antimalarial-Induced Cardiomyopathy in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Mery Deeb², Dafna D Gladman³, Paula Harvey⁴, Shadi Akhtari⁴, Susanna Mak⁵, Jagdish Butany⁶ and Murray Urowitz⁷, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toront, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁵Mecklinger Family and Posluns Family  Cardiac Catheterization Research Laboratory, University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada, ⁷Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Antimalarials (AM) are currently recommended for the management of all patients with systemic lupus erythematosus (SLE) without specific contra-indications. Their main adverse effect is…
Abstract Number: 1593 • 2017 ACR/ARHP Annual Meeting
Development of Quality Indicator Set of Systemic Lupus Erythematosus in Japan
Nobuyuki Yajima¹, Ken-ei Sada², Shingo Fukuma³, Yasushi Tsujimoto⁴, Sayaka Shimizu³, Kakuya Niihata⁵, Tsuneyo Mimori⁶, Yoshiya Tanaka⁷, Tsutomu Takeuchi⁸, Mayumi Sugiura⁹, Hitoshi Kohsaka¹⁰, Naoto Tamura¹¹, Masataka Kuwana¹², Hideto Kameda¹³, Asano Yoshihide¹⁴, Teruhisa Azuma¹⁵, Toshihiro Matsui¹⁶, Katsuya Suzuki¹⁷, Ryo Takahashi¹, Shunichi Fukuhara³ and Tatsuya Atsumi¹⁸, ¹Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan, ⁴Department of Nephrology and Dialysis, Kyoritsu Hospital, Hyogo, Japan, ⁵Division of Clinical Epidemiology, Fukushima Medical University, FUKUSHIMA, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁹Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medical sciences, Nagoya, Japan, ¹⁰Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ¹¹Rheumatology, Juntendo University, Tokyo, Japan, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹³Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ¹⁴Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ¹⁵Satellite for Teaching And Research in General Medicine, Fukushima Medical University, Fukushima, Japan, ¹⁶Department of Lifetime Clinical Immunology Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan, ¹⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: A QI set for systemic lupus erythematosus (SLE) was developed in the United States. However, this does not necessarily conform to the Japanese medical…
Abstract Number: 1594 • 2017 ACR/ARHP Annual Meeting
Bone Turnover Markers in Adults with Systemic Lupus Erythematosus
Aliese Sarkissian¹, Vidya Sivaraman², Sharon Bout-Tabaku³, Stacy P. Ardoin⁴, Melissa Moore-Clingenpeel⁵, Holly Steigelman⁶, Kelly Morris⁷ and Sasigarn Bowden⁸, ¹Pediatric Rheumatology, Nationwide Children's Hosptial and The Ohio State University Medical Center, Columbus, OH, ²Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Pediatrics and Rheumatology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁵Research, Nationwide Children's Hospital, Dublin, OH, ⁶The Ohio State University Wexner Medical Center, Columbus, OH, ⁷Rheumatology and Immunology, The Ohio State University, Columbus, OH, ⁸Pediatric Endocrinology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic inflammatory disease which has an increased risk for comorbid osteoporosis, related to the disease and long term…
Abstract Number: 1595 • 2017 ACR/ARHP Annual Meeting
Prevalence and Predictors of Depression in Patients with Systemic Lupus Erythematosus: Results from the Korean Lupus Network (KORNET) Registry
Kyung-Eun Lee¹, Ji-Hyoun Kang², Dong-Jin Park² and Shin-Seok Lee², ¹Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South)
Background/Purpose: Depression is more common in patients with systemic lupus erythematosus (SLE) than in the general population. However, few studies have investigated predictors of depression…
Abstract Number: 1596 • 2017 ACR/ARHP Annual Meeting
Effect of the Metabolic Syndrome on Organ Damage, Renal Function and Mortality in Patients with Systemic Lupus Erythematosus: A Longitudinal Analysis
Chi Chiu Mok¹, Sau Mei Tse¹ and Ling Yin Ho², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To study the effect of the metabolic syndrome (MetS) on organ damage, renal function and mortality in patients with SLE. Methods: Consecutive patients who…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].